Connect with us

Hi, what are you looking for?

POZ

HIV cases continue to rise in PH; 31% of newly-infected in March aged 24 or under

From January to March 2024, the country logged 3,410 new HIV cases, according to latest data from the Department of Health’s (DOH) HIV & AIDS and antiretroviral therapy (ART) Registry of the Philippines (HARP).

Photo by Marfil Graganza Aquino from Pexels.com

Profiteers in HIV ‘advocacy’ will celebrate the worsening numbers.

From January to March 2024, the country logged 3,410 new HIV cases, according to latest data from the Department of Health’s (DOH) HIV & AIDS and antiretroviral therapy (ART) Registry of the Philippines (HARP).

Key populations continue to be ravaged by HIV, particularly males having sex with males (MSM) (89%) and youth aged 15 to 24 (47%).

In March alone, when 1,224 new HIV cases were reported, 46% of the new cases for were aged 25 to 34, while almost a third (31%) were among the youth ages 15 to 24.

Almost all of the cases (74%) came from the National Capital Region, Central Luzon, Region 4-A (Calabarzon), Western Visayas, and Central Visayas.

In a statement, DOH Secretary Teodoro Herbosa noted that the AIDS Epidemic Model (AEM) and Spectrum suggests a continued rise in new HIV infections, expected to reach 36,700 by 2030 given the current conditions. As such, by 2030, the number of Filipinos living with HIV could increase from 215,400 in 2024 to 401,700, particularly if “services for HIV/AIDS prevention in general and PLHIV support continue to lack improvement.”

“Better health literacy including age- and culture-appropriate information and commodities for safe sex, routine HIV testing at primary care, and early access to antiretrovirals are clear directions to take,” Herbosa was quoted as saying.

Advertisement
Advertisement

Like Us On Facebook

YOU MAY ALSO LIKE

From the Editor

With the response to HIV, DOH has many issues, including the antiretroviral medicines given to Filipinos with HIV. Because isang gamot pa rin ang...

POZ

The key lies in the interaction between antibodies and T cells – the immune system’s two “rooks”.

POZ

With the new pill, most participants experienced fewer lipid-related side effects, such as increased cholesterol levels, suggesting an additional potential benefit for those at risk of heart...

POZ

The medication, anifrolumab, blocks type 1 interferon and is used to treat systemic lupus erythematosus, SLE, an autoimmune disease.

Advertisement